Ganesa, Sachita
Sule, Amrita
Sundaram, Ranjini K.
Bindra, Ranjit S.
Funding for this research was provided by:
National Institutes of Health (CA215453-02, CA215453-02, CA215453-02, CA215453-02)
OligoNation
National Brain Tumor Society
Article History
Received: 1 December 2021
Accepted: 22 March 2022
First Online: 6 April 2022
Competing interests
: R.S.B.: Cybrexa Therapeutics, Athena Therapeutics, B3 Therapeutics, and Aztek Bio; founder, consultant, equity, sponsored research. Other authors do not have competing interests.